NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia

Excerpt from the Press Release:

SHANGHAI and LEXINGTON, Mass. , May 8, 2024 /PRNewswire/ — NeuShen Therapeutics (the “Company”), a clinical-stage global biotechnology company dedicated to pioneering treatments for neurological and psychiatric disorders, today announced the dosing of the first healthy volunteer in Australia in the Phase I first-in-human clinical trial of NS-136, a novel selective M4 receptor positive allosteric modulator (M4 PAM) designed for the treatment of schizophrenia and other conditions associated with psychosis.

M4 PAM presents a novel approach to treating schizophrenia, with potential benefits in alleviating negative symptoms and cognitive impairment. It also has the potential to treat psychosis in Alzheimer’s disease or Parkinson’s disease. NS-136, developed from the Company’s proprietary small molecule R&D platform, has demonstrated significant efficacy against both positive and negative symptoms of schizophrenia in preclinical animal models, positioning it as a potential best-in-class candidate.

The Phase I clinical trial of NS-136 is a randomized, double-blind, placebo-controlled study designed to evaluate the safety and tolerability of this compound in healthy subjects. Successful results from this trial will pave the way for further clinical studies in patients with schizophrenia and other conditions associated with psychosis. The Company has also submitted an IND application to China’s National Medical Products Administration (NMPA) earlier.

Click the button below to read the entire Press Release:

Continue Reading The Press Release